ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0880

Investigating the SRPK-1-VEGF-A Alternative Splicing Pathway AsaTherapeutic Target in Arthritis
Abstract Number: 0881

Cytokine Profile of Newly Diagnosed Patients with Isolated Polymyalgia Rheumatica
Abstract Number: 0882

Brepocitinib, a Selective TYK2/JAK1 Inhibitor Under Evaluation for the Treatment of Dermatomyositis, Reduces Inflammatory Cytokine Signaling and Interferon-induced Apoptosis in Primary Human Epidermal Keratinocytes
Abstract Number: 0883

The Study of 62 Circulating Soluble Factors Is Able to Predict the Lack of Response to MTX Treatment in Recently Diagnosed DMARD Naïve Rheumatoid Arthritis Smoker and Non-Smoker Patients
Abstract Number: 0884

Genetic Architecture Divergence in Sjögren’s Disease Subphenotypes and Populations: Genome-wide Association Study of Ro/SSA+ and Ro/SSA- Cases in European Populations
Abstract Number: 0885

Reproducible Single Cell Annotation of Programs Underlying T-cell Subsets, Activation States, and Functions
Abstract Number: 0886

A Longitudinal Cohort Study Uncovers Plasma Protein Biomarkers Predating Clinical Onset and Treatment Response of Rheumatoid Arthritis
Abstract Number: 0887

Identification of Rare Variants in Lupus-causing Genes in a Mixed Paediatric and Adult Connective Tissue Disease Cohort
Abstract Number: 0888

Genetically Determined Peptidylglycine Alpha-amidating Monooxygenase (PAM) Mediated Amidation Regulates Tissue Damage by Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 0889

Unraveling the Progression of Sjögren’s Disease at the Cellular and Histological Level Using Single-cell and Spatial Transcriptomics
Abstract Number: 0890

Pervasive Inflammation Poisons Hematopoiesis and Drives Clonal Dominance in VEXAS Syndrome
Abstract Number: 0891

Shared and Disease-Specific Mechanisms of Autoimmunity Using Single Cell Sequencing of Peripheral Immune Cells
Abstract Number: 0892

Peptides from Candidate Sjögren’s Disease Autoantigens and Salivary Gland Tissue-Enriched Proteins Eluted from Human Salivary Gland HLA-DR
Abstract Number: 0893

Uncovering Common and Distinctive Molecular Profiles Between Early and Stablished Rheumatoid Arthritis Through Integrative Multi-omics Analysis and Its Association with Disease Status and Clinical Response
Abstract Number: 0894

HOXD13 Regulation of Primary Cilia in Rheumatoid Arthritis Synovial Fibroblasts: Implications for Joint-Specific Pathogenesis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].